



Newstar Medical Laboratories - Atlanta
975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144
Phone: (678) 505-8016 | Fax:(678) 806-7192
CLIA ID: 11D2145553
Laboratory Director : Robert M David, Ph.D

PATIENT DEMOGRAPHICS	Patient Name: JULIA HUHN	Account: Desert Kidney Associates Chandler	Order Code: NE22-0007281
	DOB: 07/08/1940	Provider: Mashood Qadri	Sample Type: Urine
	Patient Gender: F	Accession: 22040700002	Collected: 04/06/2022
	Patient Phone Number: (626) 827-7997	Report Status: FINAL	Received: 2022-04-07T14:18:58.288938
			Reported: 04/13/2022

PRESCRIPTION LIST	Metoprolol (Lopressor , Toprol XL) , Amlodipine (Norvasc) , Metolazone (Zaroxolyn) , Spironolactone (Aldactone) , Levothyroxine (Synthroid , Tirosint , Levoxyl) , Rosuvastatin (Crestor) , Azithromycin (Zithromax , Zithromax Z-Pak , Zmax , AzaSite) , Folic Acid (5'-methyltetrahydrofolate , 5'-MTHF , B Complex Vitamin , Vitamin B9 , Folate , Dihydrofolic Acid , Folinic Acid , Methylfolic Acid , Tetrahydrofolate) , Omega-3 polyunsaturated fatty acid () , Allopurinol (Zyloprim , Aloprim) , Apixaban (Eliquis) , Sodium bicarbonate ()	DIAGNOSIS CODES
		Z51.81, Z79.899, N18.3 Chronic kidney disease, stage 3 unspecified, I10 Hypertension

INCONSISTENT			
NOT PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
STIMULANT	Caffeine	50	> 2500
[DDI] Caffeine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. [DDI] The risk or severity of adverse effects can be increased when Metoprolol is combined with Caffeine. [DDI] Caffeine may decrease the excretion rate of Folic acid which could result in a higher serum level. [DDI] The serum concentration of Caffeine can be increased when it is combined with Allopurinol. [DDI] Levothyroxine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.			

INCONSISTENT			
PRESCRIBED		NOT DETECTED	
Class	Test	Cutoff (ng/mL)	
		"NO RESULTS"	

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Metolazone	[DDI] Spironolactone may increase the excretion rate of Metolazone which could result in a lower serum level and potentially a reduction in efficacy.	
Levothyroxine	[DDI] Sodium bicarbonate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.	
Allopurinol	[DDI] The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone. [DDI] Spironolactone may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.	
Sodium bicarbonate	[DDI] The therapeutic efficacy of Allopurinol can be decreased when used in combination with Sodium bicarbonate.	

CONSISTENT			
PRESCRIBED		DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)
BETA BLOCKER	Metoprolol	50	1917.89
[DDI] Spironolactone may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy. [DDI] Metolazone may increase the excretion rate of Metoprolol which could result in a lower serum level and potentially a reduction in efficacy. [DDI] The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Metoprolol. [DDI] Metoprolol may decrease the excretion rate of Allopurinol which could result in a higher serum level.			
CARDIOVASCULAR	Amlodipine	25	409.08
[DDI] The risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone. [DDI] Metoprolol may increase the arrhythmogenic activities of Amlodipine. [DDI] Amlodipine may increase the hypotensive activities of Metolazone.			
STATIN	Rosuvastatin	20	> 1000
[DDI] Spironolactone may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. [DDI] The excretion of Allopurinol can be decreased when combined with Rosuvastatin. [DDI] Sodium bicarbonate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. [DDI] The metabolism of Rosuvastatin can be decreased when combined with Azithromycin.			
ANTICOAGULANT	Apixaban	25	> 1250
[DDI] The risk or severity of adverse effects can be increased when Azithromycin is combined with Apixaban. [DDI] The metabolism of Apixaban can be decreased when combined with Spironolactone. [DDI] The metabolism of Apixaban can be decreased when combined with Rosuvastatin. [DDI] Caffeine may decrease the excretion rate of Apixaban which could result in a higher serum level. [DDI] The metabolism of Apixaban can be decreased when combined with Levothyroxine.			

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	6.4
Specific Gravity	1.01 - 1.03	1.013
Urine Creatinine (mg/dL)	20.00 - 400.00	106.8



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Robert M David, Ph.D

PATIENT

DEMOGRAPHICS

Patient Name: JULIA HUHN	Account: Desert Kidney Associates Chandler	Order Code: NE22-0007281
DOB: 07/08/1940	Provider: Mashood Qadri	Sample Type: Urine
Patient Gender: F	Accession: 22040700002	Collected: 04/06/2022
Patient Phone Number: (626) 827-7997	Report Status: FINAL	Received: 2022-04-07T14:18:58.288938
		Reported: 04/13/2022

NOT PRESCRIBED						NOT DETECTED	
Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)	Test	Cutoff (ng/mL)
4-Hydroxydiclofenac	50	Butalbital	100	Hydrochlorothiazide	50	Norpropoxyphene	100
Dihydrocodeine	50	Carbamazepine	50	Hydrocodone	50	Nortriptyline	50
Donepezil	50	Carbamazepine Epoxide	50	Hydromorphone	50	Norverapamil	50
Doxepin	30	Carboxyclopidogrel	50	Hydroxybupropion	50	O-Desmethyltramadol	100
Duloxetine	50	Carboxybuprofen	400	Imipramine	50	O-Desmethylvenlafaxine	100
EDDP	100	Carboxyzolpidem	50	Indomethacin	50	Olanzapine	25
N-Desmethyldiazepam	25	Carisoprodol	100	Irbesartan	50	Oxazepam	40
Risperidone	10	Celecoxib	50	Levetiracetam	50	Oxycodone	50
Ritalinic Acid	50	Chlorpromazine	25	Lorazepam	40	Oxymorphone	50
Ethyl Glucuronide	500	Clonazepam	20	Lurasidone	25	Paroxetine	25
Ethyl Sulfate	200	Clonidine	50	Meprobamate	200	Phenobarbital	100
Lisinopril	50	Codeine	50	Methadone	100	Phentermine	100
Metformin	500	Cotinine	50	Methotrexate	50	Pioglitazone	50
7-Aminoclonazepam	40	Cyclobenzaprine	50	Mitragynine	25	Pitavastatin	10
7-Aminoflunitrazepam	40	Dehydroaripiprazole	20	Morphine	50	Pregabalin	150
9-Hydroxyrisperidone	10	Desalkylflurazepam	40	Mycophenolic acid	50	Propranolol	50
Acetaminophen	400	Desipramine	50	Naloxone	10	Protriptyline	50
a-Hydroxymidazolam	30	Dextrorphan	25	Naltrexone	10	Pseudoephedrine	50
a-Hydroxytriazolam	30	Diazepam	10	Naproxen	100	Quetiapine	50
alpha-Hydroxyalprazolam	30	Diclofenac	50	N-Desmethyldiazepam	50	Rivaroxaban	50
Alprazolam	30	Digoxin	10	N-Desmethylmirtazapine	25	Salicylic Acid	400
Amitriptyline	50	Diltiazem	50	N-Desmethyldiazepam	25	Sertraline	50
Amphetamine	200	Diphenhydramine	50	N-Desmethyldiazepam	50	Sitagliptin	50
Aripiprazole	20	Fentanyl	2	Norbuprenorphine	30	Sufentanil	5
Atenolol	50	Fluoxetine	25	Nordiazepam	40	Sumatriptan	50
Atomoxetine	50	Furosemide	50	Norfentanyl	8	Tapentadol	50
Atorvastatin	10	Gabapentin	1000	Norhydrocodone	50	Temazepam	40
Baclofen	50	Glipizide	10	Norketamine	10	Topiramate	50
Buprenorphine	10	Glyburide	10	Normeperidine	100	Tramadol	100
Buspirone	50	Haloperidol	25	Noroxycodone	50	Trazodone	50

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.